![Inspira expected to enter $1.16 billion market as FDA agrees to blood oxygenation device](https://i-invdn-com.investing.com/news/LYNXNPEC0E0NI_L.jpg)
![Inspira expected to enter $1.16 billion market as FDA agrees to blood oxygenation device](https://i-invdn-com.investing.com/news/LYNXNPEC0E0NI_L.jpg)
©Reuters.
Raana, Israel – Medical technology company Inspira Technologies OXY BHN Ltd. (NASDAQ: IINN) aims to leverage $1.16 billion in perfusion funding to receive FDA clearance for the INSPIRA ART100 (1st generation) device in the first half of 2024 It is planned to be held on. system market. The company's president, Joe Ayon, announced plans to announce key results for INSPIRA ART (2nd generation), a core blood oxygenation technology that is expected to enhance direct oxygen delivery to the blood.
INSPIRA ART (Gen 2) leverages the company's proprietary HYLA blood sensor and VORTX Orbiting Blood Oxygenation and has the potential to replace current medical devices. The technology has undergone extensive testing, and the results show its suitability for the medical market, which is currently dominated by large device companies.
Hayon expressed the company's ambition to revolutionize the ventilator market and highlighted the importance of the INSPIRA ART100 (Gen 1), which acts as a cardiopulmonary bypass device. He shared a personal story that highlights the challenges with traditional ventilation methods and the need for Inspira's technology.
INSPIRA ART100 will be integrated with HYLA blood monitoring technology following FDA clearance, while INSPIRA ART (Gen 2) is being developed to perform adaptive blood oxygenation with real-time detection capabilities.
Inspira's technology is designed to help patients remain awake during treatment, reducing the need for invasive mechanical ventilation systems. Although the company's products have not yet been tested in humans or received regulatory approval, Inspira believes that FDA approval of INSPIRA ART100 is an important milestone that strengthens the company's position in the medical field. I expect it to be.
This report is based on press release statements.
Investment Pro Insights
Given Inspira Technologies' expectations for FDA approval and its potential impact on the perfusion systems market, investors are closely monitoring the company's financial health and stock price performance.according to investment professionalInspira Technologies (NASDAQ: IINN) has a market capitalization of $23.39 million, indicating the company's size in the highly competitive medical technology space.
InvestingPro tips that Inspira Technologies has more cash than debt on its balance sheet, which could give it the financial flexibility it needs to navigate the regulatory process and invest in product development. That is emphasized. Additionally, the company's stock posted strong gains last month, with a total stock return of 95.4%, reflecting investors' optimism about technological advances and market potential.
Despite these positive metrics, the company is not yet profitable, with a trailing-twelve-month P/E of -1.99 as of Q1 2023, and adjusted operating income of $12.13 million for the same period. It is a loss. These numbers highlight the high-stakes nature of Inspira's FDA clearance and market entry push.
Investors interested in learning more about Inspira Technologies' business performance and future prospects can find further information here. investment professional A total of 11 tips are listed on the platform.If you want to take advantage of this resource, please use the coupon code pro news 24 Get an extra 10% off annual or biennial Pro and Pro+ subscriptions.
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.